Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 334 of the 334 references it cites were found in a registry or an index; 174 of the 281 sources its claims cite were checked for support.

Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions

Open access
Choi, Hye Kyu, Chen, Meizi, Goldston, Li Ling, Lee, Ki-Bum · 2024 · Nano Convergence

Abstract

Integrating EVs with nanotechnology amplifies diagnostic and therapeutic capabilities, opening new avenues for managing CNS diseases.

Overview

CoChat Summary

## TL;DR

This is a review of how extracellular vesicles (EVs), often combined with nanotechnology, could improve diagnosis and treatment of central nervous system (CNS) disorders such as AD, PD, TBI, SCI, ALS, HD, and ischemic stroke. The paper argues that EVs are attractive because they can cross the BBB, carry diverse cargo, and be engineered for targeted theranostic applications, but it also emphasizes major remaining challenges in sensitivity, selectivity, stability, and delivery efficiency.

## Key findings

  • EVs are presented as natural nanoscale carriers that can cross the BBB and transport proteins, lipids, nucleic acids, and drugs, making them promising for CNS theranostics.
  • For AD, the review cites exosome-based biosensing with reported diagnostic performance such as 91.67% sensitivity, 95.00% selectivity, and 99.52% accuracy for combined exosomal miRNA-125b and miRNA-361, and another biosensor with 100% accuracy and Youden index of one for distinguishing AD from non-AD persons.
  • For PD, plasma-derived EV α-syn was reported at higher levels in PD patients (n = 94) than healthy controls (n = 50), with one study reporting an AUC of 0.769 for distinguishing PD from healthy controls; another serum EV assay reported AUC 0.78.
  • For TBI and SCI, the review highlights EV-based diagnostics and therapies, including brain-derived EV RNA profiling for TBI and multiple SCI studies in mice where EVs or engineered EVs improved repair, angiogenesis, axonal growth, inflammation, and functional recovery.

## Methods

  • This is a narrative review of the literature on EVs and nanotechnology for CNS theranostics, organized by disorder (AD, PD, ALS, HD, TBI, SCI, ischemic stroke) and by diagnostic/therapeutic application.
  • The paper synthesizes prior in vitro, in vivo, and clinical studies, including biosensor studies, biomarker studies, animal-model interventions, and examples of EV engineering and nanomaterial integration.
  • It does not report a new dataset or original statistical analysis of its own; instead, it summarizes published studies and ongoing clinical trials.

## Limitations

  • The paper states that many challenges remain, including problems with sensitivity, signal amplification, selectivity, repeatability, stability, and therapeutic delivery efficiency.
  • It notes that early detection is still not foolproof because the origins and mechanisms of many CNS disorders are not fully understood, and single biomarkers are often not sufficiently selective; this is stated in the paper.
  • It also makes evident that much of the evidence is based on preclinical in vitro and in vivo models, with the text noting a need for better in vitro models and improved clinical translation; this is evident from the review’s reliance on animal and assay studies.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s40580-024-00426-5

Cites

334 of 334 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Schematic diagram of neurological disorders and how EVs can be used in nanotechnology-assisted theranostics. (A) neurological disorders that can occur in the CNS, such as the brain and spinal cord are illustrated. Two types of representative disorders are shown: neurodegenerative diseases (AD, PD, ALS, and HD) and CNS injuries (TBI, SCI, and ischemic stroke). (B) The diagram shows how EVs can be used for the theranostics of neurological disorders. The EVs in CNS cells naturally carry biomarkers such as proteins, DNA, miRNA, and metabolites, which are vital for intercellular communication. Nano detection of EVs, therefore, can be a promising approach for the diagnosis of neurological disorders. Additionally, EVs can also be used as nanocarriers for therapeutic agents. Native EVs extracted from cells containing their own signature biomolecules can be used for nano-therapeutic methods such as microneedle patches, hydrogel transplantation, and nanomaterial injection in vivo
Fig. 1 Schematic diagram of neurological disorders and how EVs can be used in nanotechnology-assisted theranostics. (A) neurological disorders that can occur in the CNS, such as the brain and spinal cord are illustrated. Two types of representative disorders are shown: neurodegenerative diseases (AD, PD, ALS, and HD) and CNS injuries (TBI, SCI, and ischemic stroke). (B) The diagram shows how EVs can be used for the theranostics of neurological disorders. The EVs in CNS cells naturally carry biomarkers such as proteins, DNA, miRNA, and metabolites, which are vital for intercellular communication. Nano detection of EVs, therefore, can be a promising approach for the diagnosis of neurological disorders. Additionally, EVs can also be used as nanocarriers for therapeutic agents. Native EVs extracted from cells containing their own signature biomolecules can be used for nano-therapeutic methods such as microneedle patches, hydrogel transplantation, and nanomaterial injection in vivoCC BY · PubMed Central
Fig. 2 EVs-mediated intercellular communication in the CNS. The interplay of EVs with neural cells highlights their significance in both normal CNS function and pathological conditions. Under normal circumstances, EVs contribute to CNS homeostasis by supporting neuronal health, ensuring myelination, enhancing synaptic plasticity, offering neuroprotection, and providing trophic support to neurons. Conversely, in disease states, EVs originating from compromised CNS, such as dysfunctional neurons, activated microglias and reactive astrocytes cells, can propagate harmful misfolding proteins or inflammatory factors to recipient cells. This activity facilitates the progression of neurodegenerative diseases and exacerbates neuroinflammation and neural damage. Furthermore, EVs derived from CNS cells can cross the BBB and be identified in the bloodstream. The specific cargoes of these EVs can serve as biomarkers, reflecting the pathological state of their cells of origin and correlating with the stages of neurological disorders
Fig. 2 EVs-mediated intercellular communication in the CNS. The interplay of EVs with neural cells highlights their significance in both normal CNS function and pathological conditions. Under normal circumstances, EVs contribute to CNS homeostasis by supporting neuronal health, ensuring myelination, enhancing synaptic plasticity, offering neuroprotection, and providing trophic support to neurons. Conversely, in disease states, EVs originating from compromised CNS, such as dysfunctional neurons, activated microglias and reactive astrocytes cells, can propagate harmful misfolding proteins or inflammatory factors to recipient cells. This activity facilitates the progression of neurodegenerative diseases and exacerbates neuroinflammation and neural damage. Furthermore, EVs derived from CNS cells can cross the BBB and be identified in the bloodstream. The specific cargoes of these EVs can serve as biomarkers, reflecting the pathological state of their cells of origin and correlating with the stages of neurological disordersCC BY · PubMed Central
Fig. 3 Nanodiagnostic platforms for the detection of AD-derived EVs. (A) APEX assay schematics. (Top left), A representative schematic of changes in the transmission spectra with APEX amplification. (Top right), Finite-difference time-domain simulations show enhanced electromagnetic fields with back illumination. (Bottom left), and comparison of the detection sensitivities of APEX, enzyme-linked immunosorbent assay (ELISA), and western blotting. (Bottom right) Reproduced with permission from [232]. Copyright © 2019, The Author(s), (B) Schematic diagram of the detection process of the dual recognition of miRNA-193b and AβO42, Reproduced with permission from [236]. Copyright © 2023, American Chemical Society. and (C) Sensing scheme of the integrated nano-brush sensing substrate with the EGFET device (Top), SEM images show the presence of NFL-specific NDEs (white arrows), with atomic force microscopy (AFM) scan (inset) showing the surface roughness of post-NFL-sensing on nano-brush sensing substrates (Middle), schematic illustration depicting the important chemical bonds after sequential treatments and detection of NFL substances on the nano-brush sensing substrate (Bottom left), and Statistical analyses of the calibrated responses among the four tested groups (Bottom right). Reproduced with permission from [238]. Copyright © 2023, American Chemical Society
Fig. 3 Nanodiagnostic platforms for the detection of AD-derived EVs. (A) APEX assay schematics. (Top left), A representative schematic of changes in the transmission spectra with APEX amplification. (Top right), Finite-difference time-domain simulations show enhanced electromagnetic fields with back illumination. (Bottom left), and comparison of the detection sensitivities of APEX, enzyme-linked immunosorbent assay (ELISA), and western blotting. (Bottom right) Reproduced with permission from [232]. Copyright © 2019, The Author(s), (B) Schematic diagram of the detection process of the dual recognition of miRNA-193b and AβO42, Reproduced with permission from [236]. Copyright © 2023, American Chemical Society. and (C) Sensing scheme of the integrated nano-brush sensing substrate with the EGFET device (Top), SEM images show the presence of NFL-specific NDEs (white arrows), with atomic force microscopy (AFM) scan (inset) showing the surface roughness of post-NFL-sensing on nano-brush sensing substrates (Middle), schematic illustration depicting the important chemical bonds after sequential treatments and detection of NFL substances on the nano-brush sensing substrate (Bottom left), and Statistical analyses of the calibrated responses among the four tested groups (Bottom right). Reproduced with permission from [238]. Copyright © 2023, American Chemical SocietyCC BY · PubMed Central
Fig. 4 EV-based nanotherapeutic platforms for AD therapy. (A) Schematic diagram of the Lesion-Recognizing NPs and mechanism of the Lesion-Recognizing NPs for the synergistic treatment of AD (Top), Behavior improvement of the experimental mice. Time spent by mice in the target quadrant (Bottom left), Number of times the mice crossed the hidden platform (Bottom right). Reproduced with permission from [242]. Copyright © 2023, American Chemical Society, and (B) Schematic diagram of the gold nanoparticle-labeled exosome neuroimaging in AD (Top), and longitudinal homing and accumulation of MSC-exo in diseased brains (Bottom). Reproduced with permission from [244]. Copyright © 2019, American Chemical Society
Fig. 4 EV-based nanotherapeutic platforms for AD therapy. (A) Schematic diagram of the Lesion-Recognizing NPs and mechanism of the Lesion-Recognizing NPs for the synergistic treatment of AD (Top), Behavior improvement of the experimental mice. Time spent by mice in the target quadrant (Bottom left), Number of times the mice crossed the hidden platform (Bottom right). Reproduced with permission from [242]. Copyright © 2023, American Chemical Society, and (B) Schematic diagram of the gold nanoparticle-labeled exosome neuroimaging in AD (Top), and longitudinal homing and accumulation of MSC-exo in diseased brains (Bottom). Reproduced with permission from [244]. Copyright © 2019, American Chemical SocietyCC BY · PubMed Central
Fig. 5 Engineered EV constructs for treatment of PD. (A) Schematic of PR-EXO/PP@Cur preparation. (I) (ROS)-responsive amphiphilic polymer PPS − PEG, curcumin and SPIONs were self-assembled into a micellar core. (II) MSC-derived sEVs were decorated with penetratin (P) and rabies virus glycoprotein (RVG29) peptides via hydrophobic carbon chains to form PR-EXO. (III) The inner micellar core and outer PR-EXO layer were combined by extrusion to construct the PR-EXO/PP@Cur. Reproduced with permission from [262]. Copyright © 2022, American Chemical Society. (B) Schematic of EV engineered with artificial module by conjugating L-arginine (L-Arg) with methacrylate anhydride (MA) to form arginine methacrylate (M-Arg). After crosslinking with BAC, zwitterionic nanoparticles poly (meth-acrylate arginine) (PMA) were prepared. Cross-linking agent sulfo-SMCC was reacted with PMA to form PMA-SMCC, which was subsequently combined with HUMSC derived EVs to form MSCEXO/PMA capable of migrating to the upregulated ROS and iNOS in the PD microenvironment. Reproduced with permission from [263]. Copyright © 2022 Wiley-VCH GmbH
Fig. 5 Engineered EV constructs for treatment of PD. (A) Schematic of PR-EXO/PP@Cur preparation. (I) (ROS)-responsive amphiphilic polymer PPS − PEG, curcumin and SPIONs were self-assembled into a micellar core. (II) MSC-derived sEVs were decorated with penetratin (P) and rabies virus glycoprotein (RVG29) peptides via hydrophobic carbon chains to form PR-EXO. (III) The inner micellar core and outer PR-EXO layer were combined by extrusion to construct the PR-EXO/PP@Cur. Reproduced with permission from [262]. Copyright © 2022, American Chemical Society. (B) Schematic of EV engineered with artificial module by conjugating L-arginine (L-Arg) with methacrylate anhydride (MA) to form arginine methacrylate (M-Arg). After crosslinking with BAC, zwitterionic nanoparticles poly (meth-acrylate arginine) (PMA) were prepared. Cross-linking agent sulfo-SMCC was reacted with PMA to form PMA-SMCC, which was subsequently combined with HUMSC derived EVs to form MSCEXO/PMA capable of migrating to the upregulated ROS and iNOS in the PD microenvironment. Reproduced with permission from [263]. Copyright © 2022 Wiley-VCH GmbHCC BY · PubMed Central
Fig. 6 Native EVs and engineered EV constructs and therapeutic effects in ALS, HD, and ischemic stroke. (A) Improved motoneuron survival following administration of ASC-derived EVs quantified by (I) a stereological count of lumbar motoneuron and (II) Nissl staining. Reproduced with permission from [274]. Copyright © 2020 by the Authors. (B) Immunohistochemistry images of the striatum and spinal cord of R6/2 mice showing a decrease in HTT aggregates (brown spots) upon administration of XP-GFP-DNAJB6. Scale bar: 50 μm. Reproduced with permission from [280]. Copyright © 2021 by the Authors
Fig. 6 Native EVs and engineered EV constructs and therapeutic effects in ALS, HD, and ischemic stroke. (A) Improved motoneuron survival following administration of ASC-derived EVs quantified by (I) a stereological count of lumbar motoneuron and (II) Nissl staining. Reproduced with permission from [274]. Copyright © 2020 by the Authors. (B) Immunohistochemistry images of the striatum and spinal cord of R6/2 mice showing a decrease in HTT aggregates (brown spots) upon administration of XP-GFP-DNAJB6. Scale bar: 50 μm. Reproduced with permission from [280]. Copyright © 2021 by the AuthorsCC BY · PubMed Central
Fig. 7 EV-based nanotheranostics for TBI. (A) A schematic representation of RVG29 decorating on the exosome surface using click chemistry. (B) Fluorescence images of primary neurons uptake RVG29 decorated exosomes. Scale bar = 75 μm, and (C) Representative images of whole brain and cresyl violet staining after controlled cortical impact insult for lesion volume check in different treatment groups (Left) and quantification of lesion volume. (Right). Reproduced with permission from [286]. Copyright © 2023 Elsevier B.V. All rights reserved
Fig. 7 EV-based nanotheranostics for TBI. (A) A schematic representation of RVG29 decorating on the exosome surface using click chemistry. (B) Fluorescence images of primary neurons uptake RVG29 decorated exosomes. Scale bar = 75 μm, and (C) Representative images of whole brain and cresyl violet staining after controlled cortical impact insult for lesion volume check in different treatment groups (Left) and quantification of lesion volume. (Right). Reproduced with permission from [286]. Copyright © 2023 Elsevier B.V. All rights reservedCC BY · PubMed Central
Fig. 8 EV-based nanotheranostics for SCI. (A) Schematic illustration of MN-MSC patch implantation on the injury site of the spinal cord (Top), and HE staining of the injured spinal cord with MN-MSC patch implantation (Bottom left), representative images of immunohistochemical staining for MN-MSC patches on the injured spinal cord on day 7 after SCI (Bottom center), and high-magnification images of the boxed area (Bottom right). Reproduced with permission from [296]. Copyright © 2023, The Author(s). (B) The mechanism of GMPE hydrogel promoting SCI repair (Left) and myelinated axons regeneration evaluated at the 6- and 12-week time points (Right) Reproduced with permission from [299]. Copyright © 2022 The Authors. Advanced Science published by Wiley-VCH GmbH
Fig. 8 EV-based nanotheranostics for SCI. (A) Schematic illustration of MN-MSC patch implantation on the injury site of the spinal cord (Top), and HE staining of the injured spinal cord with MN-MSC patch implantation (Bottom left), representative images of immunohistochemical staining for MN-MSC patches on the injured spinal cord on day 7 after SCI (Bottom center), and high-magnification images of the boxed area (Bottom right). Reproduced with permission from [296]. Copyright © 2023, The Author(s). (B) The mechanism of GMPE hydrogel promoting SCI repair (Left) and myelinated axons regeneration evaluated at the 6- and 12-week time points (Right) Reproduced with permission from [299]. Copyright © 2022 The Authors. Advanced Science published by Wiley-VCH GmbHCC BY · PubMed Central
Fig. 9 Current challenges and future perspectives of EVs for diagnosis and treatment of CNS disorders. The challenge of utilizing EVs for CNS disorder diagnosis is the overlapping biomarkers shared amongst differing CNS disorders such as AD and PD. Another challenge is the heterogeneity of EVs derived from in vitro cell culture conditions and those derived from in vivo patient conditions. The EVs derived from different origins contain different cargoes and biomarker expressions, thus complicating biomarker discovery and diagnosis. Moreover, the challenge of isolating disease-specific EVs complicates sensitive detection for diagnosis. The current challenges of utilizing EVs for the treatment of CNS disorders include the poor targeting ability of EVs to the diseased site, the low stability of therapeutic molecules associated with EVs, and the requirement of a large number of EVs for effective therapy. To combat these limitations, EV nanoengineering presents new avenues for improving the use of EVs in diagnosis and therapy. The combination of nanomaterials such as magnetic nanoparticles can enhance the precise targeted delivery of therapeutic EVs to the diseased site. Additionally, nanomaterial-coated EVs can enhance the stability of therapeutic molecules in EVs. To enhance diagnostic potential, the incorporation of Artificial intelligence (AI) and machine learning (ML) may improve accurate and large-scale diagnosis using EVs. Furthermore, microfluidics and nanopattern assisted EV capture can isolate disease specific EVs for sensitive diagnosis as well as enrich therapeutic EVs for effective therapy
Fig. 9 Current challenges and future perspectives of EVs for diagnosis and treatment of CNS disorders. The challenge of utilizing EVs for CNS disorder diagnosis is the overlapping biomarkers shared amongst differing CNS disorders such as AD and PD. Another challenge is the heterogeneity of EVs derived from in vitro cell culture conditions and those derived from in vivo patient conditions. The EVs derived from different origins contain different cargoes and biomarker expressions, thus complicating biomarker discovery and diagnosis. Moreover, the challenge of isolating disease-specific EVs complicates sensitive detection for diagnosis. The current challenges of utilizing EVs for the treatment of CNS disorders include the poor targeting ability of EVs to the diseased site, the low stability of therapeutic molecules associated with EVs, and the requirement of a large number of EVs for effective therapy. To combat these limitations, EV nanoengineering presents new avenues for improving the use of EVs in diagnosis and therapy. The combination of nanomaterials such as magnetic nanoparticles can enhance the precise targeted delivery of therapeutic EVs to the diseased site. Additionally, nanomaterial-coated EVs can enhance the stability of therapeutic molecules in EVs. To enhance diagnostic potential, the incorporation of Artificial intelligence (AI) and machine learning (ML) may improve accurate and large-scale diagnosis using EVs. Furthermore, microfluidics and nanopattern assisted EV capture can isolate disease specific EVs for sensitive diagnosis as well as enrich therapeutic EVs for effective therapyCC BY · PubMed Central

Verification

Claims the paper makes

128 Valid · 7 Not valid · 63 Not checked · 42 Own results and interpretations

132 more claims · 77 with their cited sources checked

Create a free account to see all 240 claims and to verify the 18 references still open.

See all claims — free account
  • Probably not a substantial claim. 33
  • It may state two separate claims as one. 75

Create a free account to see these claims.

Citations

Cites

Show all 332 references

Research works printed but not linked: 9

  1. H. Lei, Z. Pei, C. Jiang, L. Cheng, Explor. (Beijing). 3(5), 20220001 (2023)
  2. Y. Ding, Y. Wang, Q. Hu, Explor. (Beijing). 2(3), 20210106 (2022)
  3. A.P. Porsteinsson, R.S. Isaacson, S. Knox, M.N. Sabbagh, I. Rubino, J. Prev. Alzheimers Dis. 8(3), 371–386 (2021)
  4. O. Hardiman, A. Al-Chalabi, A. Chio, E.M. Corr, G. Logroscino, W. Robberecht, P.J. Shaw, Z. Simmons, L.H. Van Den Berg, Nat. Reviews Disease Primers. 3(1), 1–19 (2017)
  5. C.S. Ahuja, J.R. Wilson, S. Nori, M. Kotter, C. Druschel, A. Curt, M.G. Fehlings, Nat. Reviews Disease Primers. 3(1), 1–21 (2017)
  6. M. Yanez-Mo et al., (eds.), J Extracell Vesicles 4(1), 27066 (2015)
  7. T.T. Yang, C.G. Liu, S.C. Gao, Y. Zhang, P.C. Wang, Biomed. Environ. Sci. 31(2), 87–96 (2018)
  8. J. Gill et al., Brain Inj. 32(10), 1277–1284 (2018)
  9. Y. Chen, H. Zhao, Z. Tan, C. Zhang, X. Fu, Pharmazie. 70(3), 147–154 (2015)

Cited by

See all 26

Metadata

Authors
Choi, H. K., Chen, M., Goldston, L. L., & Lee, K.-B.
Affiliations
Rutgers, The State University of New Jersey (US)
Corresponding author
Lee, Ki-Bum
Venue
Nano Convergence
Published
2024-05-13
Volume
11
Issue
1
Pages
19-19
ISSN
2196-5404 (ISSN-L)
OpenAlex
W4396857957
Cited by
26
References
332
Citations by year
2026: 9 · 2025: 15 · 2024: 2
FWCI
3.79
Type
journal article
Language
en
Open access
Licence
Locations
  • Nano Convergence (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Science Foundation (CBET-1803517, DGE-2233066)
  • New Jersey Commission on Spinal Cord Research (CSCR17IRG010, CSCR16ERG019)
  • National Institutes of Health (R21-NS132556-01, 1R01DC016612, 1R01NS130836-01A1, 3R01DC016612-01S1, 5R01DC016612-02S1, RM1 NS133003-01)
  • Alzheimer’s Association (AARG-NTF-21-847862)
  • Congressionally Directed Medical Research Programs (OCRP, OC220235P1)
  • New Jersey Commission on Cancer Research (COCR23PPR007)
  • National Heart, Lung, and Blood Institute (U01HL150852)
  • Zhou Family (Zhou Family)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Physical Sciences › Materials Science › Materials Chemistry › Advanced Nanomaterials in Catalysis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
Keywords
extracellular vesicles, nanotheranostics, central nervous system disorders, Alzheimer's disease, Parkinson's disease, traumatic brain injury, targeted drug delivery, biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions. https://app.cochat.ai/papers/10.1186/s40580-024-00426-5
The paper
Choi, H. K., Chen, M., Goldston, L. L., & Lee, K.-B. (2024). Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions. Nano Convergence. https://doi.org/10.1186/s40580-024-00426-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.